Home › Trials › NCT06313151
Clinical trial No longer in our active list Observational Ages 16 to 60

Using 2019 EULAR/ACR criteria to predict organ damage in lupus patients

Official title: The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients

Run by Sohag University · NCT06313151 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is trying to see if a new set of guidelines can help doctors predict organ damage and future health outcomes in people with lupus.

Quick facts

Study typeObservational
Ages16 Years to 60 Years
SexAll
Enrollment200 (estimated)
SponsorSohag University
Academic / other
Drugs / interventionscyclophosphamide
Locations1 site (Sohag)
Trial IDNCT06313151 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 16 and older who have been diagnosed with SLE according to the 2019 ACR/EULAR criteria and have a disease duration of more than six months.

Probably not a fit

Patients with drug-induced lupus or those with overlap syndromes such as systemic sclerosis or dermatomyositis may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to determine if the 2019 EULAR/ACR classification criteria can effectively assess organ damage and predict prognosis in patients with systemic lupus erythematosus (SLE). The study will enroll 200 SLE patients attending the Rheumatology Department at Sohag University Hospital from March 2024 to March 2025. Participants will be randomly selected and undergo comprehensive evaluations, including demographic data collection, clinical assessments, and laboratory tests to analyze disease activity and organ involvement.

Why it matters

Potential benefit: If successful, this study could enhance the ability to predict organ damage in SLE patients, leading to better management and treatment strategies.

How similar studies have gone: While the use of classification criteria in predicting outcomes is common, this specific application of the 2019 EULAR/ACR criteria in SLE is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Patient age is above 16 years old
2. Patient is classified as SLE patient according to 2019 ACR/EULAR classification criteria
3. patient with disease duration more than 6 month.

Exclusion Criteria:

1. Patient with drug-induced lupus and those with systemic sclerosis or dermatomyositis overlap syndromes .
2. patient with disease duration less than 6 month will be excluded.

Where it's running

  • Sohag University
    Sohag, Egypt     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Sohag University 122
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.